#1OH CH, ONENESS Oneness Biotech Co., Ltd Investor Presentation 4743.TT Feb 2022#2Disclaimer ONENESS This presentation contains forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Further, certain forward looking statements are based upon assumptions of future events which may not prove to be accurate. The forward looking statements in this document speak only as at the date of this presentation. Oneness Biotech does not undertake any obligation to update or revise forward looking statements in this presentation nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. | 2#3. • • • • • Oneness at a Glance Ticker: 4743 TT (IPO in 2011; MSCI Global Standard Indexes) Market Cap: ~US$ 3.4 bn (as of 2022/2/11) Headquarter & Research Site: Taipei, Taiwan Focus in chronic dermatological, immunological diseases Pipeline across pre-clinical to NDA/market stages PIC/S GMP certified Manufacturing Site: Pingtung, Taiwan ~170 Employees (as of 2022/1/31) • Science . Integrity Transparency ONENESS | 3#4Market cap at IPO USD 80mm Milestones of Innovation FB825 Exclusive licensing agreement with LEO Pharma Fespixon Fespixon market expansion 2022 US$40M + up to US$490M milestone payments Constructing PIC/s GMP Plant Taipei Exchange ONENESS IPO 2016 Founded 2011 2009 2008 Listed on Taiwan Emerging Stock Market 2020 ONENESS launched 2021 Market cap today Completed ON101 Ph3 MRCT in US., China, and Taiwan ~USD 3.4 bn | 4#5Investment Highlights ONENESS Leading Biotech Value-added strategy Strong financial standing Largest biotech company in Taiwan in terms of market cap (US$ 3.4bn) Has completed US$ 530 mn licensing deal for the atopic dermatitis new drug FB-825, the largest in Taiwan biotech history Developing First-in-Class and Best-in-Class new drug for massive unmet needs Each pipeline under development of multiple indications to maximize the value of the assets and mitigate the risk of development Sufficient cash to support upcoming development of new drugs. Anticipated profitability from the launch of Fespixon® and the licensing of new drugs | 5#6Pipeline ONENESS | 6#7Dermatology Pipeline for Unmet Medical Needs ONENESS Product Target Category Patent Indication Discovery/ Pre- clinical Phase 1 Phase 2 Phase 3 Regulatory submission 4 Taiwan FESPIXON (ON1011) M1/M2 Botanical Global Diabetic Foot Ulcer CN, SG, MY US FB825 2 CεmX mAb Global with LEO Pharma Atopic Dermatitis (AD) US Allergic Asthma (AA) Taiwan, US IND Neutrophilic Taiwan, US IND Asthma FB704A IL-6 mAb Global Chronic Kidney Disease Hepatocellular OB318 Multiple NCE Global Taiwan, US IND carcinoma³ SNS812 Virus Nucleic Acid Global with MBS COV-Flu Infection Immunology Key milestones 2022: China NDA 2023: Complete US PIII trial enrollment 2022: Complete Phase Ila study in AD; 2023: Complete Phase Ila study in AA 2023: Complete Phase II trial 2023: Complete Phase I study 1 ON101 has been completed a Phase 3 clinical trial and is undergoing another one (one for China and Taiwan registration, the other for U.S. registration). Drug approval has been obtained in Taiwan. NDA submitted to the NMPA and health authorities in South East Asia.. ON101 can potentially be used for treatment of venous leg ulcers and pressure ulcers in the future. 12 China right has been licensed to Microbio Shanghai and worldwide exclusive license jointly licensed with Micorbio Shanghiai to LEO Pharma | 3 Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer | 4 Regulatory submission includes NDA submission and Pre-NDA submission. | AD: atopic dermatitis; AA: allergic asthma 2022: File IND | 7#8ONENESS FespixonⓇ (research code: ON101) First-in-class MO Regulating New Drug for Diabetic Foot Ulcers (DFU) Billion Dollar Market Potential | 8#9Years lived with disability (millions) 20 100 120 ONENESS Back pain Depression DFU - Top 10 Costly Disease DFU has caused huge medical burden worldwide Common, Complex, Costly WHO Global Burden of Disease Diabetes Diabetes-related lower extremity complications CKD IHD CVD 1 2 3 4 5 6 7 8 9 10 11 24 25 27 >30 mn DM patients with a foot ulcer worldwide1 19-34% life-time incidence on DM patients² 30-40% recurrence on DM patients within 1 yr³ 1/3 medical costs spent on lower limbs4 1 Zhang P, et al. Ann Med. 2017 Mar;49(2):106-116. 12 N Engl J Med 2017;376:2367-75 | 3 Zhang Y, et al. Diabetes Care 2020 May; 43(5): 964-974. | 4 J Foot Ankle Res. 2020 Mar 24;13(1):16. | 9#10ONENESS DFU Treatment Market Opportunity DFU Unmet Medical Need Creates > US$ 14 Billion Market Opportunity for an Effective DFU New Drug ~US$14.8B 2030E ~US$5.1B 2024E The real market demand is anticipated to be multiplied by the launch of an effective new drug US$2.1B 2019 19.2% 2019-24E CAGR >30M DFU patients globally >1.2M amputations/year Source: Frost & Sullivan analysis, International Diabetes Federation, Diabetes Care 2014 Mar; 37(3): 651-658 | Eleftheriadou I, Tsapogas P, Tentolouris A, et al. | 10#11ONENESS Fespixon, a Novel Macrophage-regulating Drug Showed Superiority to Standard Care in a Phase 3 MRCT JAMA The Phase 3 data have been published on the leading journal Network Open. Original Investigation | Diabetes and Endocrinology Effect of a Novel Macrophage-Regulating Drug on Wound Healing in Patients With Diabetic Foot Ulcers A Randomized Clinical Trial Yu-Yao Huang, MD, PhD; Ching-Wen Lin, PhD; Nai-Chen Cheng, MD, PhD; Shawn M. Cazzell, DPM; Hsin-Han Chen, MD; Kuo-Feng Huang, MD; Kwang-Yi Tung, MD; Hsuan-Li Huang, MD; Pao-Yuan Lin, MD; Cherng-Kang Perng, MD, PhD; Bimin Shi, MD; Chang Liu, MD; Yujin Ma, MD; Yemin Cao, MD; Yanbing Li, MD; Yaoming Xue, MD; Li Yan, MD; Qiu Li, MD; Guang Ning, MD, PhD; Shun-Cheng Chang, MD Ref: JAMA Netw Open. 2021;4(9):e2122607 | MRCT: Multi-center randomized clinical trial ||11#12FAS² ONENESS Ph3 Clinical Trial Results - Superiority to SOC MRCT (US, China, Taiwan) in 236 subjects Primary endpoint- Incidence of Wound Closure1 Efficacy Endpoints Secondary Endpoint - Time to Complete Wound Closure Cumulated Incidence of Wound Closure Incidence of Wound Closure (%) 70 70 P=0.0001 60 60.7% 50 40 Probability of healing 1.0 Hazard Ratio 1.80 0.8 95% CI 1.23-2.65 P=0.002 0.6 0.4 70.0% 60.0% ON101 50.0% 40.0% 30.0% ON101, 60.7% Absorbent Dressing, 35.1% 35.1% 30 20.0% 0.2 Absorbent dressing 10.0% 0.0% 20 10 0 Wk2 (V3) Wk4 (V4) Wk6 (V5) Wk8 (V6) Wk10 (V7) Wk12 (V8) Wk14 (V9) Wk 16 (V10) 0 14 28 42 56 70 84 98 112 • ON101 Time to complete healing, d • Absorbent Dressing No. at risk 0 122 vs 114 ON101 Absorbent dressing 114 122 122 112 119 111 113 101 104 93 888 87 86 87 78 76 29 72 34 69 47 ■ON101 Absorbent Dressing (16 wks) 1 wound closure: Per US FDA guidance, complete reepithelization without drainage or requirement of dressing for consecutive 2 weeks. 2Full analysis set ON101: Trade name - Fespixon | 12 SOC: Standard of Care#13ONENESS Ph3 Clinical Trial Results - Satisfactory Safety Profile MRCT (US, China, Taiwan) in 236 subjects Safety Endpoints 62.30% TEAEs 67.50% 11.50% 7.90% 5.70% 4.40% 0% 0.90% Related TEAES Serious TEAE Related Serious TEAEs ■ON101 ■Absorbent Dressing Note: ON101 trade name: Fespixon | 13#14ONENESS Expansion into Multiple Indications Unique Mechanism for Chronic Wounds and Multi-displinary Care M1 M2 1 Pressure ulcer 2 Venous leg ulcer Pro-inflammatory Mo IL-1ẞ, Phagocytic, bactericidal Anti-inflammatory Mo Immunosuppresive, scar resolution TNF-α, IL-6 NF-κB, INOS, COX-2 TGFB1, IL-4, IL-13 3 Scar removal Podiatry | Diabetes | Dermatology Edited from DOI: 10.1007/s11926-018-0725-5 4 Radiology dermatitis | 14#15CINENESS FESPIXON cream Treatment of Diabetic Foot Ulcers ONENESS Oneness Biotech Cott FESPIXON ® Treatment of Diabetic Foot Ulcers ONENESS Fespixon® for Global Market 15 g External Use. cream 15 g. External Use Regulatory Planning Licensing and Collaboration Exclusivity & Supply Multiple NDA submissions in Asia (China, Singapore, Malaysia, Vietnam, Thailand, Philippines, Indonesia, India) Rolling submission for the US Under negotiations with multiple pharma companies for regional licensing collaboration 25 mn tubes production capacity has been established Latest patent protection for formulation till 2038 15#16ONENESS FB825 First-in-class anti-IgE B Cells mAb for Allergic Diseases Development under Global Partnership I 16#17Uptake of allergen by Promising Biologic for Allergic Disease Mast-cell stimulation – Atopic Dermatitis and Asthma Mast cell FCERI Allergen Release of mediators of acute and chronic inflammation mlgE ONENESS dendritic cells IL-4, IL-5 and IL-10 TCR IgE Precursor T helper cell Expansion of TH2-type cells B cell TH2 cell MHC class II TH1 cell Production of IgE Dendritic cell ✓ Anti-IgE Edited from Nature Review | Immunology 2004; IgE: Immunoglobuin E; AD: atopic dermatitis FB825 Anti-Cεmx cytoplasm Plasma membrane 17#18% Patients with EASI-75 ONENESS Efficacy vs Dupixent Sanofi's Dupixent (dupilumab) current best-selling biologic drug for moderate-to-severe AD 9x 69.0% FB825 2x 67% 70% 62.6% 60% 50% 40% 30% 20% 10% 0% q12w + TCS q2w + TCS qw + TCS dupilumab Ph3 trial Comparison between trials: FB825 first-patient trial (NCT0358716) vs. 2 Phase III trial of Dupixent PBO + TCS q2w + TCS qw + TCS dupilumab Ph3 trial PBO + TCS | 18#19ONENESS Outcomes in Two Exploratory Studies in AD Mean EASI Score 30 FB825 25 20 20 26.4 26.0 Reconfirmed Clinical Efficacy Changes in EASI Score 15.9 15 10 10 5 12.0 10.6 13.8 IIS with 12 moderate-to-severe AD patients (q12w) and BM study with 20 moderate-to-severe AD patients (1 dose) The change in EASI score has been similar in two studies 11.0 8.4 1 15 29 43 57 Day IIS BM Study | 19#20Product Superior Treatment to Blockbusters FB825 ONENESS Atopic dermatitis, Asthma Dupixent DUPIXENT (dupilumab) 300-2- DUPIXENT (dupilumab) Atopic dermatitis, Asthma RINVOQ RINVOG ONENESS Indication Administration SC Dose 13 doses/ year (every 4 weeks) Side effect No major side effects N/A Cost Target Cεmx N/A 2020 Global sales SC Rheumatoid arthritis, Atopic dermatitis Oral 26 doses/year (every 2 weeks) 365 tablets / year (daily dose) Allergic reactions/ eye problems Blood vessel inflammation Cold sores US$ 1,555 dose US$ 40,430 / year IL-4Ra US$ 3.5bn (AD approved in 2017, Asthma approved in 2018) 1 htps://icer.org/news-insights/press-releases/jak_inhibitor_evidence_report Common side effects: nausea, headache, and chest infections. Black-box Warning: "increased risk of serious infections, malignancy, and thrombosis" US$ 59,860 / year (upadacitinib's annual list price for RA¹) JAK1 US$ 0.7bn (RA only, approved in 2019) |20#21Dual Indications - Two Phlla Trials Final Results Anticipated in 2022 & 2023 Indication Enrollment Treatment duration Site location ONENESS Atopic Dermatitis (AD) 99 16 weeks US Final data and CSR anticipated in H1 2022 Indication Enrollment Treatment duration Site location Allergic Asthma (AA) 100 36 weeks (FB825 vs Placebo: 50 vs 50) Trial completion in H1 2023 (AA is Sponsored by Microbio Shanghai) Taiwan |21#22FB704A First-in-class anti-IL6 mAb Severe Asthma & Chronic Kidney Disease (CKD)-induced Cardiovascular Disease (CVD) ONENESS 22#23B cell ONENESS IL-6 in Severe Asthma (Neutrophil High) Severe Asthma with high neutrophils have been a large unmet need Dendritic Cells APC Th2 IL-4, 13 IL-4 Dendritic Cells APC Severe Neutrophilic Asthma affects IL6 FB704A Th17 Th1 5.5 million patients worldwide IL-5 IL-17A IFNY IgE Eosinophilic inflammation Eosinophilic asthma Eosinophil Neutrophil Neutrophilic inflammation Neutrophilic Asthma IL6 is a key cytokine to asthma (neutrophilic phenotype) Modified from Front Immunol. 2018;9:2718 Remain unmet medically Effective biologic treatment can create billion market potential | 23#24M1 Macrophage IL-6 in CKD-induced CVD 350 Million CKD Patients Worldwide at Risk of Having a CVD Cytokines, AGE Hypoxia Thrombin Ox LDL ification Vascular calcificat Monocyte/ Macrophages Endothelial Cells Smooth Muscle Cells IL-1ẞ, other cytokines IL-6 M2 Macrophage Osteoclast Cardiomyocytes Treg Th17 Circulation. 2020;141:787-789. Cardiomyocyte injury Collagen deposition/ Cardiac Fibrosis CRP, SAA, Fibrinogen ■ Approx. 700 million people worldwide live with ONENESS chronic kidney disease (CKD) which correlates with chronic inflammation. 50% CKD patients are with complication of cardiovascular diseases ■ Inflammation of CKD is correlated to the elevation of IL6. C-reactive protein (CRP) is the key indicator of inflammation. "IL-6 level and CKD status should be useful as decision support for selection of patients with chronic coronary syndrome who may derive benefit from anti- inflammatory treatment with general and specific IL-6 inhibition," | 24#25-10-2 Day 8 CRP change from base line -30- -20- 0- FB704A in Dual Indications FB704A Showed Reduction in Key Indicators for Both Indications Key indicators for CKD-induced CVD 10- Key indicator for Severe Asthma -40- Placebo FB704A Haptoglobin Vehicle FB704A low FB704A mid´ FB704A high C-Reactive Protein and Haptoglobin are reduced Neutrophils Vehicle FB704A low FB704A mid FB704A high Neutrophils are reduced | 25 ONENESS#26ONENESS Core Antibody New Drug with Strategy of Dual Indications FB825 (anti-CεmX) Atopic Dermatitis (lla)/Allergic Asthma(lla) FB704A (anti-IL6) Severe Asthma(lla) /CKD-induced CVD | 26#27ONENESS SNS812 First-in-class nucleic acid new drug for SARS-COV-2 Broad-spectrum inhibition against α, y, & & & strains |27#28ONENESS SNS812 Targets All Variants SNS812 Targets The Conserved Region And Covers 99.8% Virus Variants ORF1a E484K N501Y D614G P681H ORF1b S VOC ΙΟΛ | Alpha K417N E484K N501Y D614G A701V Beta ORF1a ORF1b K417T S E484K N501Y D614G H655Y Gamma ORF1a ORF1b S L452R T478K D614G P681R L Delta ORF1a ORF1b S From A67V to L981F, total 34 mutations Omicron ORF1a ORF1b S L452R F490S D614G Lambda ORF1a ORF1b S R346K E484K N501Y D614G P681H Mu ORF1a ORF1b S E484K D614G Q677H Eta ORF1a ORF1b lota ORF1a ORF1b S E484K D614G A701V S L452R E484Q D614G P681R Kappa ORF1a ORF1b Epsilon ORFla Theta ORF1a S L452R D614G ORF1b S ORF1b E484K N501Y D614G P681H 215 S SNS812 target | 28#29SNS812 Advantages SNS812 covers 99.8% variants and can inhibit virus by both prophylactic and post-exposure treatment. Name Classification SNS812 Nucleic acid/ siRNA Molnupiravir Small chemical/ Nucleoside analogs MK-4482 PAXLOVID Small chemical/ Protease inhibitor PF-07321332 + Ritonavir ΑΡΙ C6G25S Mechanism of action Cleavage viral RNA by siRNA targeting Cause accumulation of mutation in viral RNA Inhibit viral 3CL protease Route of administration Inhalation Oral Oral Coverage rates of variants 99.80% ND ND Resistant to viral mutation Relatively resistant viral mutation ND ND Potential drug-drug interactions of Pontential risk ND Mutagenic concern (1) Animal efficacy hACE2 transgenic mice (reduce 2.6 logs) Clinical reduction of severe illness ND Human lung transplant mice (reduce 4.4 logs) (3) 50% Ritonavir (2) BALB/c mice + mice adapted virus. (reduce 1.9 logs) (4) 89% 1. B-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. J Infect Dis. 2021 Aug 2;224(3):415-419 2. Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management. The Lancet 2022 Jan 1; 399(10319): 21-22 3. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 2021; 591: 451-457. 4. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 2021 Dec 24;374(6575):1586-1593 ONENESS | 29#30hACE2 Virus copies/ug (Log 10) SNS812 Virus Inhibition - in - in vivo Prophylatic Treatment Prevented Virus Infection ONENESS Prophylatic -D3 -D2 -D1 DO D1 D2 Viral titer Original strain(B) analysis (Lung) P < 0.0001 PFU/g (Log 10) N 8- P < 0.0001 Control SNS812 Viral RNA reduced 99.95% -Data submitted for publication- Control SNS812 Infectious virions Complete inhibition Virus copies/ug (Log 10) Prophylatic -D3 -D2 -D1 DO D1 D2 Viral titer analysis (Lung) hACE2 P < 0.0001 Delta strain(B.1.617.2) PFU/g (Log 10) 8- P < 0.0001 Control SNS812 Viral RNA Reduced 98.3% Control SNS812 Infectious virions Complete inhibition | 30#31SNS812 Virus Inhibition - in vivo ONENESS Post-exposure Treatment Showed Significant Inhibition of Viruses hACE2 Post-exposure DO D1 D2 Viral titer Original strain(B) P = 0.026 analysis (Lung) Post-exposure DO D1 D2 Viral titer analysis (Lung) hACE2 Delta strain(B.1.617.2) P=0.018 P = 0.004 P = 0.038 P = 0.012 Virus copies/ug (Log 10) 6 PFU/g (Log 10) 2 P = 0.035 Control SNS812 Viral RNA reduced 96.2% Control SNS812 Infectious virions reduced 96.1% -Data submitted for publication- 100 Relative virus RNA level (%) 10- PFU/g (Log 10) N C T C T 2 doses 3 doses Viral RNA 2 doses reduced 80% 3 doses reduced 90% C T C T 2 doses 3doses Infectious virions 2 doses reduced 90.5% 3 doses reduced 93% | 31#32ONENESS SNS812 (siRNA) Progress SNS812 targets the conserved region of SARS-COV-2. As of 2021.12.13, its target viral genome covers 99.8% of SARS-CoV2 strains including the Omicron variant according to NCBI database and GISAID ■ Contracted with CMO & CRO to proceed with GMP production and non-clinical toxicity studies. Plan to submit IND in 2022.H2 ■ SNS812 research data and results have been submitted to a renown international journal | 32#33ONENESS Upcoming 2022 and Beyond Milestones Fespixon (ON101) • Market entry into China (2022) Out-license in EU/US (2022) • Initiate rolling submission in the US (2022) FB825 • Ph2a Atopic Dermatitis completion (2022) • Ph2a Allergic Asthma completion (2023) FB704A Ph2a severe asthma (2023) • Evaluate to initiate Ph2a CKD-induced CVD (2022) SNS812 Initiate first-in-patient clinical trial (2022) | 33#34Our ESG Commitment Oneness included in 2022 Bloomberg Gender-Equality Index ONENESS 34#35ONENESS Continual Dedication into ESG - Inclusion in 2022 BGEI Oneness, the only biotech in Taiwan included in 2022 Bloomberg Gender-Equality Index(BGEI), has been dedicated to promoting gender equality issues and building a friendly workplace. In 2021, the ratio of female directors in Oneness was nearly 43 %, and women holding a management role accounted for 62.5%. Oneness scored above the global average, such as "Percent Women Of Total Workforce," "Percent Women Of Engineering Workforce," and "Percent Women Of Total Promoted Employees" established by Bloomberg, reflecting a high level of disclosure and best-in-class HR policies. Bloomberg Gender-Equality Index 2022 | 35#36Financials ONENESSS 36#375-year Balance Sheet ONENESS YoY (%) NT$ Million 2016 2017 2018 2019 2020 21Q3 2016 2017 2018 2019 2020 21Q3 TOTAL ASSETS 2,556 2,521 2,335 6,980 15,384 14,620 (9.0) (1.3) (7.4) 198.9 120.4 33.5 Cash 194 244 286.5 1202.2 6524.9 5,916.5 (72.0) 25.6 17.3 319.7 442.7 401.2 NR & AR 0.7 0.2 1.0 1.7 443.9 24.4 (6.8) (70.8) 354.6 71.4 26,277.8 (94.6) Inventory 41 41 50 48 50 67 27.9 (1.1) 23.7 (4.0) 3.8 36.7 Fixed Asset 175 456 561 640 727 723 642.7 160.8 23.1 14.2 13.5 17.0 TOTAL LIABILITIES 31 27 170 521 1,625 1,615 (24.7) (15.7) 541.0 207.1 211.9 1.4 Bank Loans NP & AP 0.2 0.1 0.5 0.6 48.4 0.8 (18.5) (53.6) 450.0 15.2 7,865.1 (98.4) TOTAL EQUITY 2,524 2,495 2,166 6,459 13,760 13,005 (8.7) (1.2) (13.2) 198.2 113.0 38.9 A/R turnover days 49 67 12 36 2,028 1,352 Inventory turnover days 4,563 12,167 1,659 1,074 1,659 1,043 A/P turnover days ROE (%) 25 (0.54) 39 9 8 830 435 (6.38) (10.75) (7.56) (2.48) (5.29) ROA (%) (0.53) (6.12) (9.69) (6.87) (2.20) (4.72) |37#385-year Income Statement ONENESS YoY (%) NT$ Million 2016 2017 2018 2019 2020 21Q3 2016 2017 2018 2019 2020 21Q3 Sales Revenue 5.7 2.6 18.9 13.5 41.6 47.6 (27.3) (54.6) 628.9 (28.5) 208.8 29.3 Gross Profit 2.9 1.4 8.2 (3.5) 23.7 32.1 (4.5) (52.1) 502.8 (142.9) (770.7) 8.8 Operating Profit (113.2) (139.1) (132.2) (311.7) (673.2) (659.6) Income before Tax (14.3) (155.9) (244.9) (326.3) (249.9) (524.0) I . Net Income to Parent (14.3) (155.4) (235.4) (322.2) (241.9) (531.4) . EPS (NT$) (0.07) (0.80) (1.20) (1.28) (0.68) (1.40) I I Key Financial ratio (%) Gross Margin 50.0 52.8 43.6 (26.2) 56.9 67.4 Operating Margin (1,984.1) (5,376.6) (701.0) (2,313.4) (1,618.0) (1,385.7) Opex ratio 2,034.1 5,429.4 744.7 2,287.2 1,674.9 1,453.4 Net Margin (250.0) (6,008.7) (1,248.6) (2,421.2) (604.9) (1,133.2) | 38#39Globalization by Innovation ONENESSS Visit us at www.onenessbio.com | 39